Press Releases
Search
-
27 Apr 2023
Press Release
bioMérieux – First-Quarter 2023 Business Review
Marcy l’Étoile (France), April 27th, 2023 – bioMérieux today releases its business review for the three months ended March 31th, 2023. Consolidated sales totaled €906 million in the first quarter of 2...
-
14 Apr 2023
Press Release
Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement
Oxford, UK and Marcy-l’Etoile, France, 14 April 2023: Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore”), the company delivering a new generation of nanopore-based molecular sensing techn...
-
13 Apr 2023
Press Release
bioMérieux receives US FDA 510(k) clearance for the BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini
Marcy-l’Étoile (France), April 13, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the fast and accura...
-
07 Apr 2023
Press Release
SPECIFIC REVEAL™ Rapid AST System, newly renamed VITEK® REVEAL™, submitted to US FDA for 510(k) clearance
Marcy l’Étoile, France, April 7 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Admini...
-
05 Apr 2023
Press Release
bioMérieux launches BIOFIRE® FIREWORKS™, a cutting-edge, data-driven software solution
Marcy-l’Étoile, France – bioMérieux, a world leader in the field of in vitro diagnostics, launches BIOFIRE® FIREWORKS™, an innovative and integrated software solution for BIOFIRE® Systems optimizing l...
-
10 Mar 2023
Press Release
BioFire Defense partners with BARDA to accelerate development of the SPECIFIC REVEAL™ Rapid AST System
Marcy-l’Étoile, France – bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Defense, LLC, its affiliate and leader in pathogen detection systems for the U.S. Depar...
-
08 Mar 2023
Press Release
bioMérieux 2022 Financial Results
Marcy l’Etoile (France) – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on March 7 under the chairmanship of Alexandre Mérieux and approved the audited...
-
08 Feb 2023
Press Release
US FDA 510(k) Clearance and CLIA-waiver for the fast and innovative BIOFIRE® SPOTFIRE® System
Marcy l’Étoile (France) – February 8th 2023 bioMérieux, a world leader in the field of in vitro diagnostics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laborato...
-
01 Feb 2023
Press Release
MAESTRIA™, a new generation microbiology middleware developed by bioMérieux
bioMérieux, a world leader in the field of in vitro diagnostics, launches MAESTRIA. This new generation middleware for the microbiology laboratory aims at providing a central software tool for the workflow management of all routine activities.
-
20 Dec 2022
Business & Solutions
CE-marking of VIDAS® KUBE™, the next generation system in the VIDAS® immunoassay portfolio
VIDAS® KUBE™ is the next generation automated immunoassay system for the renowned VIDAS® range. It will benefit clinical labs and food industries by providing results to help speed up patient care and protect consumers.
-
15 Dec 2022
Financial Information
2022 increased outlook and 2023 preview guidance
bioMérieux, a world leader in the field of in vitro diagnostics, today released its adjusted outlook for full-year 2022 and a preview of 2023 guidance.
-
16 Nov 2022
Antimicrobial Resistance
Survey bioMérieux OpinionWay - Antimicrobial Resistance and diagnostic tests
To mark World Antimicrobial Awareness Week organized by the WHO from November 18-24, bioMérieux presents the results of a bioMérieux/OpinionWay survey on the general public's knowledge of antimicrobial resistance and the use of diagnostic tests in France.
-
26 Oct 2022
Financial Information
Third-quarter 2022 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, releases its business review for the nine months ended September 30, 2022.
-
26 Sep 2022
Sepsis
New survey shows low adherence to guidelines in sepsis care puts patients at risk
Marcy l’Étoile, France and London, UK – To mark Sepsis Awareness Month, bioMérieux, a world leader in in vitro diagnostics with a long-standing commitment to the fight against sepsis, and the UK Sepsi...
-
31 Aug 2022
Financial Information
First-Half 2022 Results
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 30 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2022.